Volume : 13, Issue : 02, February – 2026
Title:
FORMULATION AND EVALUATION OF EXTENDED-RELEASE TABLETS OF AN ANTI-ISCHEMIC AGENT TRIMETAZIDINE HCL
Authors :
Asutosh Kar, Ashish Pandab, Satya Ranjan Dalai, Pravat Ranjan Guru.
Abstract :
The present study focuses on the Formulation and Evaluation of Extended-Release Tablets Of Trimetazidine Hcl, an anti-ischemic agent used in the management of angina pectoris. The primary objective was to develop a sustained-release dosage form to maintain consistent plasma drug levels, reduce dosing frequency, and improve patient compliance. Various formulations were prepared using suitable polymers and evaluated for both pre-compression and post-compression parameters, including flow properties, hardness, friability, weight variation, drug content, and in vitro drug release. All evaluated parameters were found to be within the acceptable limits as per IP standards.
Among the formulations, F2 was identified as the optimized batch, demonstrating a desirable extended drug release profile with 99.32% cumulative drug release over 12 hours. The drug release followed controlled-release kinetics, indicating the effectiveness of the matrix system used. This study concludes that the optimized formulation of Trimetazidine HCl extended-release tablets offers a promising approach for sustained therapy in ischemic conditions, ensuring better therapeutic outcomes and improved patient adherence.
Keywords: Extended-Release Tablets of Trimetazidine Hcl
Cite This Article:
Please cite this article in press Asutosh Kar et al., Formulation And Evaluation Of Extended-Release Tablets Of An Anti-Ischemic Agent Trimetazidine Hcl, Indo Am. J. P. Sci, 2026; 13(02).
REFERENCES:
1. Bhandari N., Kumar A., Choudhary A. et al. A review on immediate release drug delivery system. Int Res J Pharm App Sci. 2014;49(1):78–87.
2. Ramya Sri Sura, Cvs Subrahmanyam, Shyam Sunder Rachamalla. Design And Evaluation Of Liquisolid Compacts Of Nebivolol Hydrochloride. International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 14, Issue 2, 2022.
3. Chien YW. Oral drug delivery systems in novel drug delivery pharmaceutical technology. Marcel Dekker Inc. New York. Basel. 1992; 152-96.
4. Ali J, Khar RK, Ahuja A. A Textbook of Biopharmaceutics and Pharmacokinetics. Birla Publications Pvt. Ltd. Delhi. 2008; 252- 72.
5. Holquist C., Fava W. A look at delayed- vs. extended-release Rxs. Drug Topics. 2007 Jul 23.
6. Ramya Sri Sura, Subrahmanyam CVS, Shyam Sunder Rachamalla. Development and Evaluation of Self Micro Emulsifying Drug Delivery System (SMEDDS) for Nebivolol Hydrochloride. International Journal of Life science and Pharma Research. ijlpr 2021; doi 10.22376/ijpbs/lpr.2021.11.6.P83-97.
7. Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr. 2009;9(6):153–157.
8. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–158.
9. Cramer JA, Glassman M., Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338–342.
10. Faught E., Duh MS, Weiner JR et al. Nonadherence to antiepileptic drugs and increased mortality. Findings from the RANDOM study. Neurology. 2008;71(20):1572–1578.
11. Garnett WR, Gilbert TD, O’Connor P. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Clin Ther. 2005;27(7):1092–1103.
12. Uthman BM. Extended-release antiepilepsy drugs – review of the effects of once-daily dosing on tolerability, effectiveness, adherence, quality of life, and patient preference. US Neurol. 2014;10(1):30–37.
13. . Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr. 2009;9(6):153–157.
14. Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia. 2013;54(1):28–35.
15. Somerville KW. Bioequivalence in development of antiepileptic drugs. Epilepsy Res. 2006;68(1):82–84.